Tafinlar (dabrafenib)
Product: TAFINLAR (dabrafenib) capsules, for oral use.
Initial U.S. Approval: 2015
Strength: Capsules: 50 mg, 75 mg
Company: GlaxoSmithKline
indication: metastatic melanoma with BRAF V600E mutation. non-small cell lung cancer (NSCLC).
pharmaceuticalrawsteroids can facilitate patients and physicians access to commercially approved medicines, “Tafinlar (dabrafenib) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Tafinlar (dabrafenib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
